Staar Surgical Company ( (STAA) ) has released its Q4 earnings. Here is a breakdown of the information Staar Surgical Company presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
STAAR Surgical Company is a leading firm in the ophthalmic industry, specializing in the design, development, and marketing of implantable lenses for vision correction, particularly known for its EVO family of Implantable Collamer® Lenses (ICLs). With a global presence, STAAR provides innovative solutions for patients seeking alternatives to glasses or contact lenses.
In its latest earnings report, STAAR Surgical revealed that fiscal year 2024 was marked by challenging macroeconomic conditions in China, impacting the company’s overall performance. Despite robust sales growth outside China, the company’s net sales for the year totaled $313.9 million, with ICL sales accounting for $312.5 million. The report highlights significant declines in revenue from China, which overshadowed growth in other regions.
Key financial results show a net loss of $20.2 million for fiscal 2024, compared to a net income of $21.3 million the previous year. The gross margin decreased slightly to 76.3% from 78.4%. ICL sales excluding China rose by 13%, indicating strong demand in other markets. However, the company’s operating expenses increased by 12%, contributing to an overall operating loss.
Looking ahead to fiscal 2025, STAAR Surgical anticipates sustained growth outside China, while expecting reduced demand in the Chinese market, particularly in the first half of the year. The company plans to manage costs and optimize operations in response to current market conditions. Management remains confident in the resilience of its business model and the potential for recovery, especially in the latter half of the year.
STAAR Surgical’s management is focused on navigating these challenges by leveraging its strong balance sheet and continuing to invest in technology, surgeon education, and commercial strategies to drive future growth and market leadership.
